Skip to main content
Clinical Trials/TCTR20240527005
TCTR20240527005
Recruiting
Not Applicable

Incidence of symptomatic meibomian gland dysfunction and characteristics of meibomian gland after cataract surgery

Chulalongkorn university0 sites77 target enrollmentMay 27, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Symptomatic meibomian gland dysfunction after cataract surgery
Sponsor
Chulalongkorn university
Enrollment
77
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 27, 2024
End Date
June 30, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Able to read, understand and sign an informed consent form
  • 2\.Able and willing to comply with the follow\-up schedule and requirements
  • 3\.Patients diagnosed with cataracts with an indication for cataract surgery

Exclusion Criteria

  • 1\.Preexisting symptomatic meibomian gland dysfunction
  • 2\.Complicated cataract surgery
  • 3\.Other ocular surface diseases
  • 4\.Patients who had used artificial tears within the past 1 week or topical medication to treat another ocular disease or systemic drugs that were known to affect the tear film and ocular surface
  • 5\.History of lid spa in the past 1 week
  • 6\.History of ocular trauma, ocular surgery, and ocular infection in the past 3 months, except for those causing permanent damage to the ocular surface
  • 7\.Contact lens wearer
  • 8\.Pregnancy and lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials